{
    "clinical_study": {
        "@rank": "80660", 
        "arm_group": [
            {
                "arm_group_label": "ASP7374 group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TIV group", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture\n      derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine\n      (TIV) in adults \u226520 and <65 years."
        }, 
        "brief_title": "Study of ASP7374, Cell-culture-derived Influenza Vaccine", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Influenza", 
            "Vaccine"
        ], 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy or medically stable, as judged on the basis of history and concurrent\n             diseases.\n\n          -  Subject understands procedure of the protocol and is willing to comply with the\n             protocol.\n\n          -  Written informed consent has been obtained.\n\n        Exclusion Criteria:\n\n          -  Scheduled to receive another vaccine during the study.\n\n          -  Received influenza HA vaccine within 180 days prior to screening.\n\n          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination\n             with the study vaccine, and received or scheduled to receive an inactivated vaccine\n             or a toxoid within 7 days prior to vaccination with the study vaccine.\n\n          -  Diagnosis of immune deficit in the past, has a family member (within the third degree\n             of kinship) with a diagnosis of congenital immunodeficiency syndrome.\n\n          -  Received one of the following medications or treatment prior to vaccination with the\n             study vaccine.\n\n          -  Received one of the following medications or treatment prior to vaccination with the\n             study vaccine: Interferon formulation, Drugs which affect the immune system,\n             corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood\n             transfusion\n\n          -  History of anaphylactic shock or an allergic reaction such as generalized eruption\n             due to food (including chicken, poultry, foodstuffs derived from chicken, et al.) or\n             drug (including vaccines) allergies, fever \u226539.0\u00b0C within 2 days after the previous\n             vaccination (influenza vaccine and others)\n\n          -  History of seizures, except for febrile seizures in childhood"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961947", 
            "org_study_id": "7374-CL-0102"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP7374 group", 
                "description": "subcutaneous", 
                "intervention_name": "ASP7374", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "TIV group", 
                "description": "subcutaneous", 
                "intervention_name": "approved egg-derived TIV", 
                "intervention_type": "Biological", 
                "other_name": "Influenza HA vaccine \"SEIKEN\""
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ASP7374", 
            "Approved egg-derived vaccine", 
            "Prevention of seasonal influenza"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Study of ASP7374 \uff0dApproved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults \u226520 and <65 Years of Age\uff0d", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroconversion rate of hemagglutination inhibition (HI) antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "geometric mean titer (GMT) of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroprotection rate of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT ratio of HI antibody titer (Day 29/Day 1)", 
                "safety_issue": "No", 
                "time_frame": "Day1 and Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroconversion rate of neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "seroprotection of neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT of neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "GMT ratio of neutralizing antibody titer (Day 29/Day 1)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "measure": "Local and systemic reactions associated with the vaccination", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 8"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "UMN Pharma Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}